44 results
Page 2 of 3
8-K
EX-99.1
oc4dadcjzlh1y lw8a
15 Aug 23
Bio-path Holdings Reports Second Quarter 2023 Financial Results
7:10am
8-K
EX-99.1
1791iggj0ysg49rn3dz
7 Aug 23
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
4:42pm
424B4
u2vi98d95jrhs8
7 Aug 23
Prospectus supplement with pricing info
7:16am
8-K
EX-99.1
bhpqscnu
1 Aug 23
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
5:02pm
8-K
EX-99.1
5weyh 7u4
17 Jul 23
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
4:30pm
8-K
EX-99.1
vqnq1ta36
12 May 23
Bio-path Holdings Reports First Quarter 2023 Financial Results
7:10am
8-K
EX-99.1
zfu5ro 8c36c8veivc
10 Mar 21
Bio-path Holdings Reports Full Year 2020 Financial Results
7:11am
8-K
EX-99.1
6umi6on
13 Nov 20
Bio-path Holdings Reports Third Quarter 2020 Financial Results
7:11am